ENZC
Enzolytics Inc.

Enzolytics, Inc. (OTC PINK: ENZC) ("enzolytics.com”) (the “Company” or “Enzolytics”) disclosed today the beginning of its second collaborative effort under its three year contract with the Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences (the “Academy”). This project will seek to integrate the benefits of the Company’s exclusively licensed lyophilized pepsin with protein-engineered vaccines RtH-GD3P4 or HaH-GD3P4, produced by the Academy for the targeted use of treating melanoma.

The Company recently reported on a study conducted at the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria concluding that Chief Science Officer of ENZC and inventor Harry Zhabilov’s patented experimental cancer lyophilized pepsin treatment, is effective in decreasing the growth and spread of cancer cells in breast cancer, colon cancer, prostate cancer, cancer of the larynx, as well as small cell lung cancer. The report prepared by Prof. Genova-Kalu and Prof. Dr. Ivaristova concludes with the statement that “In conclusion, lyophilized pepsin has extremely promising biomedical potential.”

Additionally the Academy performed In Vito test on IPF, the active ingredient in the lyophilized pepsin treatment, concluding that a polypeptide complex of lyophilized pepsin, causes cytopathological changes and significantly reduces the survival and/or proliferative activity of the cell cultures used as experimental models. The tested substance exhibits the strongest cytotoxic/cytostatic effect on mammary adenocarcinoma (MCF-7 and MDA-MB-231 lines), cervical carcinoma (HeLa line), colorectal carcinoma (CaCo-2 line) and adenocarcinoma of the prostate (PC-3). A cytotoxic/cytostatic effect was observed on cells from small cell lung cancer (A 549 line) and the line Hep-2 (carcinoma of the larynx). The observed effect was time and concentration dependent, a response that is most likely due to the different biological characteristics of the malignant neoplasms from which the model cell lines were derived, as well as to the phenomenon of heterogeneity of tumor cells.

In a separate research report funded by the ‘National Science Fund’, Bulgaria, and ‘National Science Program Young Scientists and Postdoctoral Researchers’, it was demonstrated that the administration of the protein-engineered vaccines RtH-GD3P4 or HaH-GD3P4 suppressed tumor growth, decreased tumor incidence, and prolonged the survival of treated animals. The immunization of experimental mice induced an infiltration of immunocompetent cells into the tumors and generated cytotoxic tumor-specific T cells in the spleen. The treatment also generates significantly higher levels of tumor-infiltrated M1 macrophages, compared to untreated tumor-bearing control mice. This study demonstrated a promising approach for cancer therapy having potential applications for cancer vaccine research. The treatment also generates significantly higher levels of tumor-infiltrated M1 macrophages. The study demonstrates a promising and novel approach for cancer therapy with potential applications for cancer vaccine research.

RtH-GD3P4 and HaH-GD3P4 exhibited a strong anti-tumor immune response. Research results showed several mechanisms for tumor suppression after immunization with two Hc-based epitope vaccines under different regimens of treatment, demonstrating a promising approach for cancer therapy with potential applications for cancer vaccine research.

The Company and Academy are dedicated to searching for and finding new effective compounds of natural origin for composing anti-tumor vaccines and believe this collaborative effort to combine the benefits of their promising Intellectual Properties towards the treatment of Malignant Melanoma Cancer, is the first step in achieving the goal to accelerate discovery of combined applications and commercialization of their technologies. The Company and Academy stated that their initial focus will be combining Monoclonal Antibodies and Immune Therapeutic Proteins (“ITP”) for the development of treatments of malignant antigens.

Harry Zhabilov, Chief Science Officer of ENZC stated, “Over the last several decades and I believe into the foreseeable future cancer has and will be a leading cause of death worldwide necessitating the development of new treatments, including anti-cancer vaccines. One of the fastest growing forms in both men and women is Melanoma skin cancer. Several monoclonal antibodies and different anticancer vaccines which show encouraging results are being studied that combing ENZC’s treatment may lead to positive results.”

Steve Sharabura, the CEO of Enzolytics commented, “The current predominate forms of treatments for cancer are radiation and chemotherapy, both of which can and in most cases do affect other functions of the patient. With all the positive outcomes of the research and testing of ENZC’s licensed treatment since joining the company I believe we can make a difference.”

About Enzolytics, Inc.

Enzolytics, Inc. is transitioning from solely a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted service areas of sales, marketing and distribution focusing on medical devices, medical testing and nutraceutical products.

Forward Looking Statements

The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company’s ability to enter into a definitive business combination agreement and Company’s ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company’s ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company’s stockholders and the amount of funds remaining in Company’s trust account after satisfaction of such requests; those factors discussed in Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading “Risk Factors,” and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company’s expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company’s assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company’s assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.

CONTACT INFORMATION

Enzolytics, Inc.

Steve Sharabura, Chief Executive Officer

1101 Raintree Circle, Suite 130
Allen, Texas 75013

Tel: (845) 925-4597

 X/Twitter: @EnzolyticsInc